$GNPX

Genprex, Inc. is studying the TUSC2 gene in its REQORSA therapy for potential applications in aging, beyond oncology. The company's collaboration with Meharry Medical College explores mitochondrial biology and cellular aging. Genprex will present findings at the GSA 2026 conference on Nov. 4.

Genprex reported peer-reviewed research showing TUSC2 loss disrupts mitochondrial function and protein homeostasis in mice, with stronger effects in males. The study, conducted by Meharry Medical College, links TUSC2 to aging-related decline in the hippocampus. Human data show TUSC2 decreases with age in most brain regions and is reduced in Alzheimer’s datasets. The findings expand understanding of TUSC2 beyond oncology. GNPX filed this information with the SEC.

Genprex (NASDAQ: GNPX) said it selected a U.S. CDMO to scale up manufacturing of its AAV-based diabetes gene therapy. The CDMO will produce cGMP drug product for IND-enabling preclinical studies and future clinical trials, including process optimization, scale-up, and analytical assay qualification. The program targets T1D and T2D.

After-hours gainers included Profusa (PFSA) after a 1-for-4 reverse split, with shares outstanding cut to about 605,726. INVO Fertility (IVF) rose after Q2 results: revenue about $2.2M (+17% YoY) and net income about $0.9M. Amylyx (AMLX) traded higher ahead of Phase 3 LUCIDITY topline results on Aug 18, 2026. Vogenx (VOGX) and others also gained.

Genprex (NASDAQ:GNPX) said it is collaborating with Roche Diagnostics to validate NSCLC patient-selection biomarkers using Roche’s TROP2 antibody. Genprex cited data linking high TROP2 H-scores and low PTEN H-scores with longer progression-free survival. Roche will run assay validation, expected by end-2026, for Genprex’s NSCLC trials.

Genprex (GNPX) shares fell 12.4% in pre-open trading after a Roche Diagnostics collaboration announcement. The deal aims to validate TROP2 and PTEN biomarkers for patient selection in non-small cell lung cancer trials, building on Genprex’s Reqorsa Gene Therapy preclinical findings. The stock initially rose about 3% before reversing; no analyst or insider changes were cited.

Genprex Inc. (NASDAQ:GNPX) shares rose about 3% after it said Roche Diagnostics will collaborate to validate TROP2 biomarker assays for patient selection in non-small cell lung cancer trials. Roche will use its TROP2 antibody, also used in an FDA-designated companion diagnostic. Genprex expects validation by late 2026, then integration into its NSCLC program.

Genprex, Inc. (GNPX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 ex_976935.htm EXHIBIT 10.1 ex_976935.htm Exhibit 10.1 GENPREX, INC. 2018 EQUITY INCENTIVE PLAN As Amended and Restated Effective April 15, 2026 (the “ Restatement Date ” ) 1. Purposes of the Plan. The purposes of this Plan are to attract and retain personnel for positio

Ayrton Capital LLC, Alto Opportunity Master Fund (Segregated Master Portfolio B), and Waqas Khatri have reported beneficial ownership of 249,788 shares of Genprex, Inc. common stock, exercisable through warrants. This represents a 2.69% stake, based on 9,044,856 shares outstanding as of March 27, 2026, and is subject to a 9.99% beneficial ownership blocker. The filing is a routine disclosure of derivative-based ownership, as the holdings are under 5% and include an ownership cap.

This article highlights three oversold healthcare stocks – Medtronic (MDT), Option Care Health (OPCH), and Genprex (GNPX) – that could see upward movement in Q2, based on a Relative Strength Index (RSI) near or below 30. It details recent company news, stock performance, and RSI values for each, suggesting an opportunity for investors to consider undervalued companies. The piece utilizes Benzinga Pro data to identify these potential breakouts.